MedinCell S.A. (LON:0ACH)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 749.70M +63.6% |
| Revenue (ttm) | 21.20M -12.4% |
| Net Income | -27.32M |
| EPS | -0.82 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102 |
| Open | 24.50 |
| Previous Close | 24.24 |
| Day's Range | 24.26 - 24.50 |
| 52-Week Range | 15.60 - 39.38 |
| Beta | 0.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 8, 2026 |
About MedinCell
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria... [Read more]
Financial Performance
In fiscal year 2026, MedinCell's revenue was 24.28 million, a decrease of -12.44% compared to the previous year's 27.73 million. Losses were -31.29 million, 69.7% more than in 2025.
Financial numbers in EUR Financial StatementsNews
Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable tr...
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a recor...
Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at...
Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align deb...
MedinCell Slides: Corporate presentation
MedinCell has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
MedinCell Transcript: H2 25/26
Strong royalty growth from UZEDY and pipeline expansion drove recurring revenues, despite a net loss due to increased R&D and business development investments. Olanzapine LAI is on track for a late 2026 launch, with meaningful revenues expected in 2027.
MedinCell Earnings release: H2 2026
MedinCell released its H2 2026 earnings on June 16, 2026, summarizing the period's financial results.
MedinCell Slides: H2 2026
MedinCell has posted slides in relation to its H2 2026 quarterly earnings report, which was published on June 16, 2026.
Medincell Reports FY 2025-26 Annual Results
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): Key Financial Highlights Total revenues €24.3 million, including €9.3 million of UZEDY® royalties, confirming the evolution of the reve...
MedinCell Transcript: Jefferies Global Healthcare Conference 2026
Long-acting injectable products are driving rapid revenue growth, with UZEDY outperforming forecasts and olanzapine LAI poised for approval and launch later this year. Strategic partnerships, a robust pipeline, and next-generation technology underpin a catalyst-rich outlook for 2026.
Medincell: Videoconference and Publication of Annual Financial Results, Tuesday, June 16, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announ...
Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749
(RTTNews) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the Marketing Authorizatio...
MedinCell Transcript: R&D Day 2026
Strong adoption of UZEDY and anticipated approval of olanzapine LAI validate the platform approach, while strategic partnerships and robust IP drive long-term royalty growth. Platform innovation and lifecycle management strategies expand opportunities in chronic diseases and beyond.
Medincell to Host an Online R&D Day on Tuesday, May 12, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) will host an online R&D Day, held in English, on Tuesday, May 12, 2026, from 4:00 to 5:30 pm CEST (10:00 - 11:3...
Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatme...
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell's (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with the publication of its Q4 and ...
MedinCell Transcript: H1 25/26
Olanzapine LAI FDA filing and UZEDY's strong growth drive a 50% revenue increase and improved operating loss. The pipeline advances with AbbVie and Gates Foundation-backed programs, while a robust cash position supports future growth.
MedinCell Quarterly report: H1 2026
MedinCell has published its H1 2026 quarterly earnings report on December 9, 2025.
MedinCell Earnings release: H1 2026
MedinCell released its H1 2026 earnings on December 9, 2025, summarizing the period's financial results.
MedinCell Slides: H1 2026
MedinCell has posted slides in relation to its H1 2026 quarterly earnings report, which was published on December 9, 2025.
MedinCell Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong growth is expected from UZEDY and the upcoming long-acting olanzapine, which addresses key safety and compliance issues. Market adoption of LAIs is accelerating, with significant commercial potential in both the US and Europe.
MedinCell Transcript: Jefferies London Healthcare Conference 2025
A transformative period is underway, with strong UZEDY sales, a robust pipeline led by long-acting olanzapine, and global health initiatives. Profitability is targeted for 2027, with new technologies and partnerships fueling future growth.
Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...